Condition: B-Cell Non-Hodgkin Lymphoma-Recurrent · B-Cell Non-Hodgkin Lymphoma-Refractory · Sponsor: Tianjin Medical University Cancer Institute and Hospital
A phase I, open-label clinical study to evaluate the safety, tolerability, and efficacy of LUCAR-G39D, a dual-targeted cell preparation targeting CD19/CD20, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.
This description comes directly from the study's public registry record.
Huilai Zhang · +86-18622221228 · huilaizhangtz@163.com
Kaiyang Ding · 13966672170 · dingkaiy@126.com
Always discuss trial participation with your own doctor first.
| Oncology Department, The First Affiliated Hospital of USTC west district | Hefei, Anhui, China | Recruiting |
| Tianjin Cancer Hospital | Tianjin, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06395870